|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.03.26 - 15:15
|
NANOBIOTIX Statement Regarding Recent Media Speculation (GlobeNewswire EN)
|
|
|
PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today issued the following statement in response to recent media speculation concerning intentions for a potential public take-over....
|
|
|
|
|
|
|
25.02.26 - 22:18
|
NANOBIOTIX to Participate in Investor Conferences in March (GlobeNewswire EN)
|
|
|
PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in these upcoming conferences in March:...
|
|
|
15.12.25 - 08:36
|
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris (GlobeNewswire EN)
|
|
|
PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices....
|
|
|
|
|
24.11.25 - 22:18
|
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook (GlobeNewswire EN)
|
|
|
PARIS and CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ''Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today reported an operational update and financial results for the third quarter of 2025 along with an outlook for clinical updates from studies sponsored by Nanobiotix or The University of Texas MD Anderson Cancer Center (“MD Anderson”) expected in 2026 and announced the closing of its non-dilutive royalty financing transaction with HCRx....
|
|
|
|
|
|
|
11.11.25 - 22:18
|
NANOBIOTIX to Participate in Jefferies London Healthcare Conference (GlobeNewswire EN)
|
|
|
PARIS and CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at the following conference:...
|
|
|
03.11.25 - 22:18
|
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th (GlobeNewswire EN)
|
|
|
PARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences:...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
